PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	10/764131-Conf. #6072
Filing Date	January 23, 2004
First Named Inventor	Tibor KELER
Art Unit	1636
Examiner Name	Not Yet Assigned
Attorney Docket Number	MXI-099CN

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AW	A1*	US-6,682,928-A1	02-27-2003	Keler et al.	
	A2*	US-4,470,925	09-11-1984	Auditore-Hargreaves	
	A3*	US-4,676,980	06-30-1987	Segal et al.	
	A4*	US-4,954,617	09-04-1990	Fanger et al.	
	A5*	US-5,635,600	06-03-1997	Fanger et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
AW	B1*	DE-19634159	09/1997			
	B2*	WO-91/00360-A1	01-10-1991	Medarex, Inc.		
	B3*	WO-91/05871	05/1991			
	B4*	WO-91/03493	03/1992			
	B5*	WO-92/05793	04/1992			
	B6*	WO-92/10591	06/1992			
	B7*	WO-92/15322	09/1992			
	B8*	WO-94/10332	05-11-1994	Tempest, Philip R. et al.		
	B9*	WO-95/09917	04/1995			
	B10*	WO-96/40789	12/1996			
	B11*	WO-97/07218	02/1997			
	B12*	WO-97/20048	06/1997			
	B13*	WO-97/35004	09/1997			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
AW	C1	Guyre et al. (1997) Canc. Immunol. Immunother., vol. 45, 146-148, 1997.*	
	C2	Daeron et al. (1997) Annu. Rev. Immunol., vol. 15, 203-234, 1997.*	
	C3	Miller et al. (1995) FASEB, vol. 9, 190-199, 1995.*	
	C4	Deonarain et al. (1998) Exp. Opin. Ther. Patents, vol. 8 (1), 53-69, 1998.*	
	C5	Anderson, C. et al. (1986) "Stimulation of Superoxide Production by a Monoclonal Antibody (mab) Against the High Affinity IgG Fc Receptor (FcRI) of U937 Cells", Fed. Proc., 45: 714, Abstract #3247. *	
	C6	Ball, E. et al. (1992) "Initial Trial of Bispecific Antibody-Mediated Immunotherapy of CD15-Bearing Tumors: Cytotoxicity of Human Tumor Cells Using a Bispecific Antibody Comprised of Anti-CD15 (MoAb PM81) and Anti-CD64/Fc.gamma.RI (MoAb32)", J. of Hematotherapy, 1:85-94. *	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	10/764131-Conf. #6072
Filing Date	January 23, 2004
First Named Inventor	Tibor KELER
Art Unit	1636
Examiner Name	Not Yet Assigned
Attorney Docket Number	MXI-099CN

AW	C7	Brennan, M. et al. (1985) "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G.sub.1 Fragments", Science, 229: 81-83. *	
	C8	Chang, T. W. (1985) "Regulation of immune response by antibodies: the importance of antibody and monocyte Fc receptor interaction in T cell activation", Immun. Today, 6:245. *	
	C9	Chen, J. et al. (1985) "An Immunoconjugate of Lys3-Bombesin and Monoclonal Antibody 22 Can Specifically Induce FcgammaRI (CD64)-Dependent Monocyte- and Neutrophil-Mediated Lysis of Small Cell Carcinoma of the Lung Cells", Clinical Cancer Research, 1 (4):425-434. *	
	C10	Clark, M. et al. (1990) "Use of Bispecific Monoclonal Antibodies to Treat Hematological Malignancies: A Model System Using CD3 Transgenic Mice", Bispecific Antibodies and Targeted Cellular Cytotoxicity, Edited by Romet-Lemonne et al., Fondation Nationale de Transfustion Sanguine, Les Ulis, France, pp. 243-247. *	
	C11	de Leij, L. et al. (1990) "Intrapleural and Intraperitoneal Application of Bispecific Antibody Retargeted Lymphocytes to Cancer Patients", Bispecific Antibodies and Targeted Cellular Cytotoxicity, Edited by Romet-Lemmone et al., Fondation Nationale de Transfusion Sanguine, Les Ulis, France, pp. 249-253. *	
	C12	de Palazzo, I. et al. (1990) "Potentiation of Tumor Lysis by a Bispecific Antibody that Binds to CA19-9 Antigen and the Fc.gamma. Receptor Expressed by Human Large Granular Lymphocytes", Cancer Research, 50:7123-7128. *	
	C13	Dillman, R. (1989) "Monoclonal Antibodies for Treating Cancer", Annals of Interal Medicine, 111:592-603. *	
	C14	Ericson, S. et al. (1994) "The Effect of Recombinant Human Interleukin-3 and Recombinant Human Granulocyte-macro-Phage Colony-Stimulating Factor on Fc.gamma. Receptor Expression and Antibody-Dependent Cellular Cytotoxicity of Hematopoietic Progenitor Cells During in Vitro Myeloid Maturation", Experimental Hematology, 22:283-289. *	
	C15	Falo et al. (1995) "Targeting antigen into the phagocytic pathway in vivo induces protective tumor immunity", Nat. Med. 1:649. *	
	C16	Fanger, M. et al. (1994) "Production and Use of Anti-FcR Bispecific Antibodies" Immunomethods 4 (1): 72-81. *	
	C17	Fanger, M. et al. (1992) "Fc.gamma. Receptors in Cancer and Infectious Disease", Immunol. Res., 11:203-216. *	
	C18	Fanger, M. et al. (1992) "Bispecific Antibodies" Critical Reviews in Immunology, 12 (3,4):101-124. *	
	C19	Gosselin et al. (1992) "Enhanced antigen presentation using human Fcg receptor (monocyte/macrophage)-specific immunogens", J. Immun. 149:3477. *	
	C20	Graziano, R. et al. (1995) "Construction and Characterization of a Humanized Anti-Gamma-Ig Receptor Type I (Fcgamma RI) Monoclonal Antibody" The Journal of Immunology, 155 (10): 4996-5002. *	
	C21	Guyre, P. et al. (1989) "Monoclonal Antibodies that Bind to Distinct Epitopes on Fc.gamma.RI are able to Trigger Receptor Function", The Journal of Immunology, 143 (5), pp. 1650-1655. *	
	C22	Guyre, P. et al. (1983) "Recombinant Immune Interferon Increases Immunoglobulin G Fc Receptors on Cultured Human Mononuclear Phagocytes", Journal of Clinical Investigation, 72:393-397. *	
	C23	Harris, W. et al. (1993) "Therapeutic Antibodies--The Coming of Age", Tibtech, 11:42-44. *	
	C24	Hird, V. et al. (1990) "Immunotherapy with Monoclonal Antibodies", Genes and Cancer, Edited by D. Carney and K. Sikora, Chapter 17, pp. 183-189. *	
	C25	Isturiz, M. et al. (1991) "Two Different Fc.gamma. Receptor-Dependent Cytotoxic Mechanisms Triggered by Monoclonal Immunoglobulins", Immunology Letters, 29:271-276. *	
	C26	Jung, Gundram, et al., 1991, "Target Cell-Induced T cell Activation with Bi- and Trispecific Antibody Fragments", Eur. J. Immunol., 21:2431-2435. *	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	10/764131-Conf. #6072
Filing Date	January 23, 2004
First Named Inventor	Tibor KELER
Art Unit	1636
Examiner Name	Not Yet Assigned
Attorney Docket Number	MXI-099CN

AW		C27	Karpovsky, B. et al. (1984) "Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fc.gamma. Receptor Antibodies", Journal of Experimental Medicine, 160:1686-1701. *	
		C28	Kovacsovics-Bankowski et al. (1993) "Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages", Proc. Natl. Acad. Sci. USA, 90:4942. *	
		C29	Liu, M. et al. (1985) "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes", PNAS, 82:8648-8652. *	
		C30	Looney, R. et al. (1986) "Human Monocytes and U937 Cells Bear Two Distinct Fc Receptors for IgG", The Journal of Immunology, 136 (5):1641-1647. *	
		C31	Lubeck, M. et al. (1985) "The Interaction of Murine IgG Subclass Proteins with Human Monocyte Fc Receptors", The Journal of Immunology, 135 (2):1299-1304. *	
		C32	Mabondzo, A. et al. (1994) "Antibody-dependent Cellular Cytotoxicity and Neutralization of Human Immunodeficiency Virus Type 1 by High Affinity Corss-Linking of gp41 to Human Macrophage Fc IgG Receptor Using Bispecific Antibody", Journal of Virology, 75:1451-1456. *	
		C33	Nitta, T. et al. (1990) "Preliminary Trial of Specific Targeting Therapy Against Malignant Glioma", The Lancet, 335:368-376. *	
		C34	Perez, P. et al. (1985) "Specific Targeting of Cytotoxic T Cells by Anti-Target Cell Antibody", Nature, 316:354-356. *	
		C35	Repp, R. et al. (1994) "G-CSF Stimulated Neutrophils As Effector Cells In Immunotherapy With A Bispecific Antibody to FcgammaRI and To HER-2/neu (MDX210): Preclinical Studies", Immunobiology, 191 (2-3): 250-251. *	
		C36	Sarmay, G. et al. (1992) "Mapping and Comparison of the Interaction Sites on The Fc Region of IgG Responsible for Triggering Antibody Dependent Cellular Cytotoxicity (ADCC) Through Different Types of Human Fc.gamma. Receptor", Molecular Immunology, 29 (5):633-639. *	
		C37	Schlom, J. (1991) "Monoclonal Antibodies: They're More and Less Than You Think", Molecular Foundations of Biology Edited by Williams and Wilkins, Chapter 6, pp. 95-134. *	
		C38	Shen, L. et al. (1984) "Direct Stimulation of ADCC by cloned Gamma Interferon is not Ablated by Glucocorticoids: Studies Using a Human Monocyte-like Cell Line (U-937)", Molecular Immunology, 21 (2):167-173. *	
		C39	Shen, L. et al. (1986) "Heteroantibody-Mediated Cytotoxicity: Antibody to the High Affinity Fc Receptor for IgG Mediates Cytotoxicity by Human Monocytes that is Enhanced by Interferon-.gamma. and is not Blocked by Human IgG", The Journal of Immunology, 137 (11): 3378-3382. *	
		C40	Shu, Liming, et al., "Generation and characterization of a single-gene encoded single-chain immunoglobulin-interleukin-2 fusion protein," *Immunotechnology*, Vol. 1:231-241 (1995)	
		C41	Valerius, T. et al. (1993) "Involvement of the High-Affinity Receptor for IgG (Fc.gamma.RI; CD64) in Enhanced Tumor Cell Cytotoxicity of Neutrophils During Granulocyte Colony-Stimulating Factor Therapy", Blood, 82 (3): 931-393. *	
		C42	van de Winkel, J. et al. (1993) "Human IgG Fc Receptor Heterogeneity: Molecular Aspects and Clinical Implications", Immunology Today, 14 (5): 215-221. *	
		C43	Waldmann, T. (1991) "Monoclonal Antibodies in Diagnosis and Therapy", Science, 252:1657-1662*	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Anne Marie Wehbe/ (07/13/2006)	Date Considered	07/13/2006